RxDoctor Payments Data

Marcos Yang, MD

Family Medicine · Palos Verdes Estates, CANPI 1023087392

Payments from drug & device makers

$4,976in general payments, 2019–2025

Across 118 payments — averaging $42.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amarin Pharma, Inc.$1K
  • AstraZeneca$1K
  • Amgen$667
  • AbbVie$348
  • Stryker$158
  • Boston Scientific$148
  • plus $1K from 13 others

What the payments were for

  • Food & beverage$4,976100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,976 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$92,802
Medicare patients
179
Services billed
1,890

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VascepaIcosapent Ethyl48$29,896
ProliaDenosumab13$22,600
JanuviaSitagliptin Phosphate14$20,207
FarxigaDapagliflozin Propanediol26$17,885
Icosapent Ethyl31$7,807
EliquisApixaban12$6,753
Atorvastatin Calcium548$5,230
Valsartan149$3,278
EdarbyclorAzilsartan Med/Chlorthalidone13$3,196
Olmesartan Medoxomil160$3,075
SynthroidLevothyroxine Sodium28$2,646
Omega-3 Acid Ethyl Esters38$2,571
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide68$2,304
Levothyroxine Sodium187$2,281
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide45$1,719

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenProlia$667$22,60013 claims
MerckJanuvia$95$20,20714 claims
AstraZenecaFarxiga$1,141$17,88526 claims
PfizerEliquis, Paxlovid$112$8,18224 claims
Arbor Pharmaceuticals, Inc.Edarbyclor$72$3,19613 claims
AbbVieSynthroid$348$2,64628 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.

Other family medicine in Palos Verdes Estates

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →